GCCTI Workshop Report

Summary provided by Associate Professor Jeanne Tie. 

The Genomic Cancer Clinical Trials Initiative (GCCTI) works to support the 14 national cooperative cancer clinical trials groups (CTGs) funded under Cancer Australia’s Support for Cancer Clinical Trials program to develop cancer clinical trial protocols (grant applications for studies involving two or more cancer types and two or more cooperative trials groups). Associate Professor Jeanne Tie attended the GCCTI’s last workshop, held on 11 October.

1. Anti-ROR1 – presented by Carolyn Ford

  • ROR1 over-expressed in leukaemia and a variety of solid malignancies
  • anti-ROR1 antibody Cirmtuzumab trial in CLL showing some promise
  • The ROMEO study being pursued by ANZGOG in ovarian and endometrial cancer (high ROR1 expressing tumour)
    • Single arm phase II – Cirmtuzumab + paclitaxel – PI Sumitra Ananda and Janine Lombard
  • Other high ROR1 expressing tumour include pancreas cancer
  • ROR1 also over-expressed in CRC and is associated with poor prognosis – potentially a new therapeutic target?

2. Australian Exceptional Responders Program – presented by Megan Barnet

  • Kinghorn Cancer Centre/Garvan – aiming to recruit and analyse patients nationally with an exceptional response to cancer therapy defined as:
    • CR or PR, where <10% of patients would be expected to respond
    • CR or PR that lasts > 3 times the median / expected PFS
    • Best response PD where >90% of patients would be expected to respond
  • Kinghorn will initiate telehealth consultation for consent
  • Blood sample (2x10mL tubes) and access to archival tissue
    • Sequencing/targeted analysis
  • The workshop suggested that the investigator approach each cooperative group to prioritise the tumour types of interest to be included in this program

3. Adoptive T cell therapy using patient’s own TIL (lifileucel – TIL therapy) – presented by Anthony Joshua

  • Developed by IOVANCE
  • Given with high dose IL-2 – requires 4 days in ICU – needs to be done in selected Phase I unit
  • Focus has been on immune-responsive tumours, e.g. melanoma, H&N, NSCLC
  • Interesting concept but unlikely of interest for AGITG
Share